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ness to treatments. Typical outputs from these simula-
tions are patient functional status, life years, quality-ad-
justed life years, and associated costs, all of which can be
appropriately discounted. The output information is pre-
sented in the form of distributions which can be used to
estimate mean or median values and confidence intervals
for the outcomes of interest. These results can be used to
compute cost-effectiveness ratios and other drug value
measures. Monte Carlo disease simulation also allows de-
cision makers to address the question of risk associated
with smaller populations that may not tend to the "aver-
age" results generated by Markov models or simulations
of large populations. In this workshop, we describe how
to create a Monte Carlo simulation model and how dif-
ferent types of uncertainty can be incorporated into the
model. We will briefly compare and contrast Monte
Carlo and Markov simulation techniques. Discussion
topics will be illustrated and motivated by an HIV/AIDS
model of the effect of combination antiretroviral therapy
on viral load and CD4 progression. This workshop
should be beneficial to outcomes researchers and health
care decision makers who need to incorporate uncer-
tainty about the natural history of a disease and the im-
pact of alternative disease management strategies for in-
dividual patients into their drug value analyses.
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Results from economic analyses of the effectiveness of
new therapeutic innovations determine whether a new
product will be reimbursed by a managed care organiza-
tion or government agency. Often, the results of these
economic analyses are presented as formal empirical
analyses in scientific journal articles. With the pace of
medical innovations submitted for approval on a payers
fee schedule or formulary list ever increasing, it is impor-
tant to convey the results of analysis as effectively and ef-
ficiently as possible. In response, interactive computer
models have been developed to present the key findings
of an economic analysis. Ideally, these models allow a po-
tential buyer to customize a scientific analysis to deter-
mine their own reservation price for a new product. The
quality and costs of these software applications vary
greatly. Given the resources expended to develop these
models and time to produce them, it useful to examine
the features of cost-effective "laptop model" design. This
workshop will review an inventory of the features of lap-
top models. Participants will gain an understanding of
the development process and costs for developing these
models from the conceptual development phase to pro-
duction of a stand-alone software application. A checklist
of critical ingredients for software development will be
reviewed with a special focus on role of a multidisci-
plinary development team and the capital resources re-
85
quired. A review of the discordance between scientists,
biomedical manufactrures, software applications devel-
opers and potential clients and methods to gain consen-
sus to build the application will be discussed. Examples
from Project HOPE's and other firms' software develop-
ment initiatives will be demonstrated as successful appli-
cations currently in use. Participants with a basic knowl-
edge of computer applications, cost-effectiveness methods,
and systems analysis will likely gain the most from this
workshop.
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Combining the measurement of traditional drug utiliza-
tion and other health care resources can provide a good
measure of performance within a health care plan, but
they have not been extensively developed. Following the
workshop, participants should be able to select medical
conditions in a population that are appropriate for drug
usage performance measures, develop a set of drug-based
performance measures from well-established treatment
guidelines, develop appropriate denominators for the per-
formance measures and monitor the results within and
across health care plans. A template and the criteria de-
velopment process for two drug-based performance sets
(asthma and otitis media) will be presented. The role of
performance measures to evaluate trends and to describe
the consequences of implementing managed care to a tra-
ditional Medicaid program will be discussed. Providers
and insurers of health care who are responsible for qual-
ity of care indicators or the drug and disease evaluation
process will benefit from attending this workshop.
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The choice of data used in decision modeling of health
care interventions divides analysts into two groups: those
who favor randomized clinical trial (RCT) data and those
who prefer "real world" data. This decision may have se-
rious consequences if the end result is to inform health
care policy. This workshop employs a case study to (1)
show how differences in the reality of clinical practice
and the rigor of RCTs can lead to biases when decision
models use RCT data to evaluate policy issues and (2)
provide a method of updating decision models with
claims/outcomes data to overcome this bias. We highlight
